With a passion for understanding moments of discovery, Nicole delivers litigation-based strategies to protect your most valuable life science IP
Nicole Conlon, PhD, brings significant patent litigation experience to her practice of assisting clients with pre-litigation strategy, due diligence investigations, contentious patent office proceedings, freedom-to-operate analyses, and prosecution portfolio management. Nicole offers particular expertise in monoclonal antibodies, gene editing and recombinant nucleic acid technologies, vaccine products, and immunological therapies.
Nicole has defended and challenged pharmaceutical patents to protect her clients’ blockbuster products. She represented innovator companies in high-stakes district court actions, often involving parallel IPR proceedings. Her trial experience includes biologics cases, arbitrations, and Hatch-Waxman litigation. Nicole’s IPR experience spans all stages, from developing PTAB petitions, preparing patent owner responses, and handling depositions, through preparations for oral hearing. Across her cases, Nicole developed patent validity strategy, drafting winning briefs, including summary judgment motions, and preparing expert reports. She also gained a special tact for working with inventors and experts to convey the science and to prepare them to carry the day in court.
Nicole’s litigation perspective translates into strategic and creative solutions to her clients’ complex legal and technical issues. She dives deep into the technology and works with clients to understand their needs and deliver efficient, thoughtful advice. Nicole approaches her practice with enthusiasm from a passion for uncovering and understanding moments of discovery.
Nicole joins McNeill Baur PLLC after practicing as an attorney at Patterson Belknap Webb & Tyler LLP and after several years at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Before entering patent law practice, Nicole earned her PhD in Immunology from Stanford University. In her graduate work, she identified antigen-specific T cells in the autoimmune disease lupus and studied the molecular structure of T-cell receptors by x-ray crystallography. While at Stanford, Nicole won a National Science Foundation (NSF) Fellowship. She also served as Managing Editor of the Stanford Journal of Law, Science & Policy, committed to developing cross-disciplinary content on issues confronting stem cell therapies.
“INSIGHT: FDA Approves First-Ever RNAi-based Therapy,” Bloomberg Law, 2018 (coauthor).
“Tetramers Reveal IL-17-Secreting CD4+ T Cells That Are Specific for U1-70 in Lupus and Mixed Connective Tissue Disease,” PNAS, 112 (10): 3044-49, 2015 (coauthor).
“Characterization of Influenza Vaccine Immunogenicity Using Influenza Antigen Microarrays,” PLoS One, 8(5): e64555, 2013 (coauthor).
“Self-Antigen Recognition by Follicular Lymphoma B-Cell Receptors,” Blood, 120(20): 4182-90, (coauthor).
“Reform Law Would Allow For Quick Challenges to Patents,” The National Law Journal, May 9, 2011 (coauthor).
“Patent Legislation - Meeting the Challenges of Reform?,” Intellectual Property Today, January 28, 2011 (coauthor).
“Editor’s Note: What We Can Do With What We Inherit: Shaping the Future of Stem Cell Research and Policy,” Stan. J. L. Sci. & Pol’y, 3: 36-41, 2010 (coauthor).
“The U1-snRNP Complex: Structural Properties Relating to Autoimmune Pathogenesis in Rheumatic Diseases,”Immunol. Rev., 233(1): 126-45, 2010 (coauthor).
“Elucidation of the Interleukin-15 Binding Site on its Alpha Receptor by NMR,” Biochemistry, 46(33): 9453-61, 2007 (coauthor).
“How a Single T Cell Receptor Recognizes Both Self and Foreign MHC,” Cell, 129(1): 135-46, 2007 (coauthor).
“Engineering and Characterization of a Stabilized Alpha1/Alpha2 Module of the Class I Major Histocompatibility Complex Product Ld,” J. Bio. Chem., 281(35): 25734-44, 2006 (coauthor).